| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
IDEXX Laboratories, Inc.
$556.69
+1.7 (+0.31%)
Market Cap
43.86 B
EPS
14.47
P/E Ratio
38.48 $
Value Trade
345.19 M
-0.5 %
Week
-1.96 %
1 Month
-1.78 %
3 Month
-12.57 %
6 Month
3.12 %
5 Year
59,072.99 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
628.49 K
52 Week Range
518.55 - 769.98
% held by Insiders
0.38 %
% held by Institutions
97.65 %
Enterprise Value
44.15 B
Total Shares
78.78 M
Short %
2.47 %
Float Shares
78.58 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for IDEXX Laboratories, Inc.
1Total events
0Upcoming
0Tier-1 (high impact)
2026 – 2026Coverage
Event history 1
TBD
●Quarterly UpdateCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in IDXX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
IDXX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
IDXX▲ +0.3%today
IDEXX Laboratories to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
IDEXX Laboratories, a leader in pet healthcare, announced participation in the Morgan Stanley 24th Annual Global Healthcare Conference. CEO Mike Erickson and CFO Andrew Emerson will engage in a fireside chat on September 14, 2026. This event will be accessible via a live audio webcast, enhancing investor engagement.
Read more →IDXXIDEXX Laboratories to Release 2026 Second Quarter Financial Results
IDEXX Laboratories is set to announce its financial results for the second quarter of 2026. The release will provide insights into the company's performance and financial health during this period. Investors and stakeholders are likely to closely monitor these results for future guidance.
Read more →IDXXIDEXX Expands Fecal Dx Antigen Testing Platform with Taeniid Tapeworm Detection
IDEXX Laboratories has expanded its Fecal Dx antigen testing platform to include taeniid tapeworm detection. This enhancement allows for the detection of more intestinal parasites, improving early treatment options for pets. The platform has seen significant adoption since its launch, with over 50 million tests conducted globally. The new testing feature will be available at no extra cost to IDEXX Reference Laboratories customers in the U.S. and Canada starting in late June.
Read more →IDXXIDEXX Laboratories to Present at Stifel Conference and Announces 2026 Investor Day
IDEXX Laboratories has announced its participation in the upcoming Stifel Conference and also revealed plans for an Investor Day in 2026. This event aims to engage with investors and provide insights into the company's future strategies and developments. Further details about the conference and Investor Day are anticipated.
Read more →IDXXIDEXX Laboratories Announces First Quarter Results
IDEXX Laboratories recently announced its first quarter results, but the article does not provide any details regarding the financial performance or key metrics. The lack of information leaves stakeholders without insights into the company's current status. Overall, the announcement appears to be underwhelming due to the absence of critical data.
Read more →IDXXIDEXX verkündet die Verfügbarkeit des Cancer Dx Tests zur Früherkennung von Lymphomen bei Hunden in Deutschland
IDEXX has announced the availability of its Cancer Dx test for early detection of lymphomas in dogs in Germany. This test aims to enhance veterinary diagnostics and improve outcomes for canine patients. The launch reflects IDEXX's commitment to advancing pet healthcare through innovative solutions.
Read more →IDXXIDEXX Laboratories to Release 2026 First Quarter Financial Results
IDEXX Laboratories is set to announce its financial results for the first quarter of 2026. The release will provide insights into the company's performance during this period. Further details regarding the results and any potential implications for stakeholders are anticipated.
Read more →IDXXIDEXX Laboratories Announces Fourth Quarter and Full Year 2025 Results
IDEXX Laboratories reported robust financial results for Q4 and full year 2025, with revenues reaching $1,091 million, a 14% increase year-over-year. The Companion Animal Group drove growth, supported by innovations like IDEXX Cancer Dx. The company anticipates continued growth into 2026, projecting revenues between $4.632 billion and $4.720 billion.
Read more →IDXXIDEXX Advances the Future of Veterinary Cancer Care with Comprehensive Mast Cell Tumor Testing for Dogs
IDEXX Laboratories announced advancements in veterinary cancer diagnostics, including the addition of mast cell tumor detection to its Cancer Dx Panel, set to launch in mid-2026. The IDEXX inVue Dx FNA Cytology will also roll out in late 2025, allowing for rapid in-clinic diagnosis. These innovations aim to improve early detection and treatment outcomes for canine cancer.
Read more →IDXXLowest-Dose Radiography Meets Next-Level Imaging: IDEXX Launches ImageVue DR50 Plus
IDEXX Laboratories has launched the ImageVue DR50 Plus, a cutting-edge digital imaging system for veterinary practices. This system significantly reduces radiation exposure while providing high-definition, AI-powered imaging. It aims to enhance diagnostic accuracy and workflow efficiency, particularly benefiting veterinary teams and their patients. The system is now available in the U.S. and Canada.
Read more →IDXXIDEXX Announces CEO Succession
IDEXX Laboratories has announced the promotion of Michael Erickson to President and CEO, effective May 12, 2026. Jonathan Mazelsky will transition to Executive Chair and retire after the 2027 annual meeting. The leadership change is part of a planned succession, with both leaders emphasizing IDEXX's commitment to innovation and growth in veterinary healthcare.
Read more →IDXXIDEXX Announces CEO Succession Michael Erickson, PhD, to Succeed Jay Mazelsky as President and CEO; Mazelsky to Serve as Executive Chair of the Board of Directors
IDEXX Laboratories, Inc. has announced the promotion of Michael Erickson, PhD, to President and CEO effective May 12, 2026. This transition follows Jay Mazelsky's leadership and will see him take on the role of Executive Chair. Dr. Erickson has been with IDEXX since 2011 and has significant experience in healthcare technology. The Board believes that this succession is well-planned and positions IDEXX for ongoing success in the veterinary diagnostics industry.
Read more →IDXX▲ +14.8%on this news
IDEXX Laboratories Announces Third Quarter Results Achieves third quarter revenue growth of 13% as reported and 12% organic, and CAG Diagnostics recurring revenue growth of 11% as reported and 10% organic. Strong organic
IDEXX Laboratories, Inc. announced impressive third quarter results for 2025, reporting revenues of $1,105 million, a 13% increase year-over-year. Key growth drivers included a 14% rise in the Companion Animal Group and a 17% increase in Livestock, Poultry, and Dairy segments. The company also improved its earnings per diluted share to $3.40, marking a 21% increase. IDEXX plans to update its full year revenue growth guidance, reflecting strong ongoing performance and optimistic market conditions.
Read more →IDXXIDEXX Laboratories Elects Karen Peacock to Board of Directors
IDEXX Laboratories has elected Karen Peacock to its Board of Directors, effective October 6, 2025. Peacock, a seasoned executive with significant experience in B2B, SaaS software, and AI, is expected to complement the existing board's expertise. She has previously held leadership roles at Intercom and Intuit and is anticipated to contribute to advancing IDEXX's goals in pet healthcare innovation. Lawrence D. Kingsley, the Board Chair, expressed confidence in her ability to enhance the Board's effectiveness.
Read more →IDXX▲ +27.5%on this news
John Ravis, Investor Relations, 1-207-556-8155 IDEXX Laboratories Announces Second Quarter Results Achieves second quarter revenue growth of 11% as reported and 9% organic, supported by CAG
IDEXX Laboratories announced strong second quarter results for 2025, reporting revenues of $1,109 million, up 11%. The growth was primarily driven by the Companion Animal Group, which saw a revenue rise of 11% and increased diagnostic utilization through innovative technologies. Earnings per diluted share soared to $3.63, reflecting a 49% increase year-over-year. IDEXX also revised its full-year revenue and EPS guidance upward, citing solid performance in diagnostics and favorable foreign currency impacts.
Read more →IDXXIDEXX Laboratories Elects Joseph L. (Jay) Hooley to Board of Directors
IDEXX Laboratories has elected Joseph L. (Jay) Hooley to its Board of Directors, effective July 10, 2025. Hooley is recognized for his significant executive experience, having led State Street Corporation through a period of growth. His expertise is expected to enhance the board's effectiveness, supporting IDEXX's mission in the pet healthcare industry. The board now consists of ten directors, with nine being independent.
Read more →IDXX▲ +9%on this news
John Ravis, Investor Relations, 1-207-556-8155 IDEXX Laboratories Announces First Quarter Results Achieves first quarter revenue growth of 4% as reported and 5% organic, supported by CAG Di
IDEXX Laboratories, Inc. has reported its first-quarter results for 2025, achieving a revenue of $998 million, which reflects a 4% increase as reported and a 5% organic growth. The company highlighted the successful launch of its IDEXX Cancer Dx, a diagnostic tool aimed at early detection of canine lymphoma, which may enhance treatment options for pet healthcare. IDEXX also increased its earnings per share by 5% compared to the previous year. Furthermore, the company updated its full-year revenue guidance, projecting a slight increase in growth expectations, despite some external economic factors.
Read more →IDXX▲ +11.1%on this news
John Ravis, Investor Relations, 1-207-556-8155 IDEXX Laboratories Announces Fourth Quarter and Full Year 2024 Results Achieves fourth quarter revenue growth of 6% as reported and on an orga
IDEXX Laboratories announced its fourth quarter and full year 2024 financial results, highlighting a 6% increase in quarterly revenue to $954 million, driven by growth in the Companion Animal Group. The company reported a 13% rise in earnings per share for the quarter, supported by significant innovations, including the upcoming launch of the IDEXX Cancer Dx screening for canine lymphoma. However, results were impacted by currency fluctuations and litigation expenses. Looking ahead, IDEXX provided initial 2025 revenue guidance projecting growth between 4% and 7%.
Read more →IDXXIDEXX Laboratories Announces Increase in Share Repurchase Program Authorization
IDEXX Laboratories has announced the authorization for an increase in its share repurchase program, allowing for the buyback of up to five million additional shares. This decision follows the 1.3 million shares remaining under the existing program as of December 3, 2024. The company maintains the flexibility to execute these repurchases at management's discretion, supporting its commitment to enhancing shareholder value.
Read more →IDXXIDEXX Announces CFO Transition Brian McKeon to Retire from IDEXX in June 2025 Andrew Emerson, Senior Vice President, Corporate and CAG Finance, to Serve as IDEXX's Next
IDEXX Laboratories announced the retirement of CFO Brian McKeon effective June 1, 2025, with Andrew Emerson set to succeed him as CFO starting March 1, 2025. Emerson, a key financial leader within the company since 2015, aims to continue the company's growth trajectory and profitability. McKeon will assist during the transitional phase to ensure stability. The company also reaffirmed its 2024 full-year guidance, reflecting confidence in its financial outlook.
Read more →IDXXVia Diligent Messenger
Jonathan W. Ayers has announced his resignation from the Board of Directors of IDEXX Laboratories, effective November 8, 2024. He previously served as the Chairman, President, and CEO of the company from 2002 to 2019 and has been an independent board member for the last five years. In his farewell letter, Ayers expressed gratitude for the opportunity to serve and highlighted the growth opportunities ahead for IDEXX. He also offered his assistance to the company post-resignation.
Read more →IDXX▼ -9.8%on this news
John Ravis, Investor Relations, 1-207-556-8155 IDEXX Laboratories Announces Third Quarter Results Achieves third quarter revenue growth of 7% as reported and 6% organic, supported by CAG Di
IDEXX Laboratories reported a revenue growth of 7% for the third quarter of 2024, amounting to $976 million. Growth was primarily driven by the Companion Animal Group, which saw a 7% increase, alongside a notable 13% rise in Water revenues. Despite these gains, the company adjusted its full-year organic revenue growth guidance downward and reported a decline in revenues from the Livestock, Poultry and Dairy segment. The operating margin improved, and the company maintained a consistent EPS outlook, though it noted the impact of ongoing litigation on financial projections.
Read more →IDXXJohn Ravis, Investor Relations, 1-207-556-8155 IDEXX Laboratories Announces Second Quarter Results Achieves second quarter revenue growth of 6% as reported and 7% organic, supported by CAG
IDEXX Laboratories reported a 6% increase in revenues for the second quarter of 2024, driven by strong growth in its Companion Animal Group and Water segments. Despite increasing revenue, earnings per share saw a reduction due to litigation-related expenses. IDEXX also revised its full-year revenue growth forecasts downward, reflecting trends in U.S. clinical visit levels. The company indicated strong demand for its veterinary software and diagnostic solutions, which suggests a solid foundation for future growth.
Read more →IDXX▼ -5%on this news
John Ravis, Investor Relations, 1-207-556-8155 IDEXX Laboratories Announces First Quarter Results Achieves first quarter revenue growth of 7% as reported and organic, supported by CAG Diagn
IDEXX Laboratories announced a 7% increase in revenue for the first quarter of 2024, totaling $964 million, driven mainly by growth in its Companion Animal Group and Water revenue. While recurring revenue from the Companion Animal Group remained strong at 7%, the Livestock, Poultry, and Dairy segment experienced a 3% decline. Forecasts for 2024 revenue growth have been updated to a range of 6.5% to 8.5%, reflecting adjustments for foreign currency impacts and customer contract resolutions from Q1 2023.
Read more →IDXX▲ +8.5%on this news
IDEXX Announces Fourth Quarter and Full Year Results Achieves fourth quarter revenue growth of 9% reported and 8% organic, driven by CAG Diagnostics recurring revenue growth of 11% reported and 10% organic Solid growth s
IDEXX Laboratories reported strong financial results for the fourth quarter and full year ending 2023, with a revenue increase of 9% to $902 million. Recurring revenue from the Companion Animal Group (CAG) grew substantially, indicating solid demand for their diagnostic products and services. The company anticipates continued growth into 2024, projecting a revenue increase between 7.5% and 10.5%. However, challenges remain, as some sectors, including Livestock, Poultry, and Dairy revenues, experienced declines.
Read more →IDXXIDEXX Laboratories Announces Third Quarter Results Achieves third quarter revenue growth of 9% reported and 8% organic, driven by CAG Diagnostics recurring revenue growth of 10% reported and 9% organic Solid revenue grow
IDEXX Laboratories reported a strong performance in its third quarter results for 2023, showcasing a 9% increase in revenue with significant growth in its Companion Animal Group and veterinary software segments. The company achieved a 10% growth in recurring revenue from diagnostics, driven by high interest in its innovations. However, challenges such as lower herd health screening internationally impacted revenue from livestock services, and fluctuations in currency affected its financial outlook. The overall financial outlook for 2023 remains optimistic with updated guidance indicating continued growth.
Read more →IDXXIDEXX Laboratories Announces Second Quarter Results Records second quarter revenue growth of 10% reported and 10% organic, driven by CAG Diagnostics recurring revenue growth of 11% reported and 12% organic Achieves recor
IDEXX Laboratories reported strong second-quarter results, with revenues reaching $944 million, showing a 10% increase both reported and organically. The Companion Animal Group drove significant growth, with diagnostics recurring revenue rising by 11%. Earnings per diluted share rose by 71% compared to the previous year. However, revenue from Livestock, Poultry, and Dairy remained flat, and the company anticipates some headwinds from foreign exchange impacts on its operating margin forecasts.
Read more →IDXXI DEXX Laboratories Elects Irene Chang Britt to Board of Directors
IDEXX Laboratories has announced the election of Irene Chang Britt to its Board of Directors, effective July 11, 2023. Ms. Britt is a seasoned executive with a decade-long experience at Campbell Soup Company and has held various roles at other prominent firms. Her appointment aims to strengthen IDEXX's leadership and strategic direction in the pet healthcare sector. IDEXX emphasizes its commitment to innovation and enhancing the health of pets and livestock.
Read more →IDXXIDEXX Laboratories Announces First Quarter Results Achieves first quarter revenue growth of 8% reported and 10% organic, driven by CAG Diagnostics recurring revenue growth of 9% reported and 12% organic Strong organic re
IDEXX Laboratories reported strong first quarter results for 2023, including a revenue increase of 8% reported and 10% organic, driven by robust growth in Companion Animal Group (CAG) Diagnostics. The company achieved significant gains in premium instrument placements and veterinary software revenues. However, the Livestock, Poultry and Dairy (LPD) segment experienced a 5% decline in revenues. Additionally, currency fluctuations impacted earnings per share, highlighting the effects of foreign exchange on financial performance.
Read more →IDXXIDEXX Laboratories Announces Fourth Quarter and Full Year 2022 Results Achieves fourth quarter revenue growth of 3% reported and 7% organic, driven by CAG Diagnostics recurring revenue growth of 4% reported and 8% organi
IDEXX Laboratories reported fourth quarter revenues of $829 million, marking a 3% increase year-over-year, with 7% organic growth. The Companion Animal Group saw notable organic revenue growth driven by solid diagnostic demand and expansion of veterinary software solutions. However, the company's full-year earnings per share fell by 7% due to earlier R&D investments and currency impacts. Despite some challenges, IDEXX maintains an optimistic revenue guidance for 2023, projecting continued growth in both revenue and earnings.
Read more →IDXX▲ +9.8%on this news
IDEXX Laboratories Announces Third Quarter Results Achieves third quarter revenue growth of 4% reported and 8% organic, driven by CAG Diagnostics recurring revenue growth of 5% reported and 9% organic, building on high p
IDEXX Laboratories Announces Third Quarter Results WESTBROOK, Maine, Nov. 1, 2022 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced third quarter results and an update on U.S. companion animal diagnostics trend
Read more →IDXXIDEXX Laboratories Announces Second Quarter Results Achieves second quarter revenue growth of 4% reported and 6.5% organic, driven by CAG Diagnostics recurring revenue growth of 4% reported and 7% organic, building on hi
IDEXX Laboratories Announces Second Quarter Results WESTBROOK, Maine, Aug. 2, 2022 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced second quarter results, as well as an update on U.S. companion animal diagnos
Read more →IDXX▼ -5.7%on this news· ran to -21% by day 3
IDEXX Laboratories Announces First Quarter Results Achieves first quarter revenue growth of 8% reported and organic, driven by CAG Diagnostics recurring revenue growth of 8% reported and 9% organic, building on high prio
IDEXX Laboratories Announces First Quarter Results WESTBROOK, Maine, May 4, 2022 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, today announced first quarter results
Read more →IDXXIDEXX Laboratories Announces Fourth Quarter and Full Year 2021 Results
IDEXX Laboratories Announces Fourth Quarter and Full Year 2021 Results WESTBROOK, Maine, Feb. 2, 2022 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, today announced
Read more →IDXX▼ -5.9%on this news
IDEXX Laboratories Announces Third Quarter Results
IDEXX Laboratories Announces Third Quarter Results WESTBROOK, Maine, Nov. 2, 2021 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, today announced third quarter resul
Read more →IDXXIDEXX Laboratories Announces Second Quarter Results
IDEXX Laboratories Announces Second Quarter Results WESTBROOK, Maine, July 30, 2021 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, today announced second quarter re
Read more →IDXXIDEXX Laboratories Announces Fourth Quarter and Full Year 2020 Results
IDEXX Laboratories Announces Fourth Quarter and Full Year 2020 Results WESTBROOK, Maine, Feb. 2, 2021 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), today announced fourth quarter and full year results, as well as market condition updates. Fourth Quarter and Full Yea
Read more →IDXXIDEXX Laboratories Elects Dr. Asha S. Collins to Board of Directors
IDEXX Laboratories Elects Dr. Asha S. Collins to Board of Directors WESTBROOK, Maine, Nov. 12, 2020 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, announced today th
Read more →IDXXIDEXX Laboratories Announces Fourth Quarter and Full Year 2019 Results
IDEXX Laboratories Announces Fourth Quarter and Full Year 2019 Results WESTBROOK, Maine, Jan. 31, 2020 /PRNewswire/ IDEXX Laboratories, Inc. (NASDAQ: IDXX), reports revenues of $605 million for the fourth quarter of 2019, an increase of 10% compared to the prior year period on
Read more →IDXXIDEXX Laboratories Announces Leadership Changes Jay Mazelsky Appointed President and Chief Executive Officer and Elected to IDEXX Board Jonathan Ayers Will Continue as a Member of the IDEXX Board and Serve as a Senior Ad
IDEXX Laboratories Announces Leadership Changes Jay Mazelsky Appointed President and Chief Executive Officer and Elected to IDEXX Board Jonathan Ayers Will Continue as a Member of the IDEXX Board and Serve as a Senior Advisor to the Company Lawrence Kingsley Assumes Role of In
Read more →IDXXIDEXX Laboratories Elects Sam Samad to Board of Directors
EX-99.1 2 exhibit991.htm EXHIBIT 99.1 Exhibit EXHIBIT 99.1 FOR IMMEDIATE RELEASE IDEXX Laboratories Elects Sam Samad to Board of Directors WESTBROOK, Maine, July 18, 2019 - IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice sof
Read more →IDXXIDEXX Laboratories Chairman, President and Chief Executive Officer, Jonathan Ayers, Taking Medical Leave of Absence Jay Mazelsky, Executive Vice President, Companion Animal Group, Appointed Interim President and Chief Ex
IDEXX Laboratories Chairman, President and Chief Executive Officer, Jonathan Ayers, Taking Medical Leave of Absence WESTBROOK, Maine, July 1, 2019 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and
Read more →IDXXIDEXX Laboratories Announces Fourth Quarter and Full Year 2018 Results
IDEXX Laboratories Announces Fourth Quarter and Full Year 2018 Results WESTBROOK, Maine, Feb. 1, 2019 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, reports revenue
Read more →IDXXIDEXX Laboratories Announces Fourth Quarter and Full Year 2017 Results
IDEXX Laboratories Announces Fourth Quarter and Full Year 2017 Results WESTBROOK, Maine, Feb. 1, 2018 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, reports revenue
Read more →IDXXIDEXX Laboratories Announces Estimated Impact of U.S. Tax Reform
IDEXX Laboratories Announces Estimated Impact of U.S. Tax Reform WESTBROOK, Maine, Jan. 5, 2018 /PRNewswire/ -- IDEXX Laboratories, Inc. ( IDEXX or the Company ) (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testin
Read more →IDXXIDEXX Laboratories Announces Second Quarter Results - Achieves revenue growth of 9% on a reported basis and 10% on an organic basis, driven by CAG Diagnostics recurring revenue growth of 12% reported and 13% organic - De
IDEXX Laboratories Announces Second Quarter Results WESTBROOK, Maine, Aug. 1, 2017 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, reports revenues for the second qua
Read more →IDXXIDEXX Laboratories Elects Stuart M. Essig to Board of Directors
IDEXX Laboratories Elects Stuart M. Essig to Board of Directors WESTBROOK, Maine, July 17, 2017 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, today announced the un
Read more →IDXXIDEXX Laboratories Announces Increase in Share Repurchase Program
FOR IMMEDIATE RELEASE IDEXX Laboratories Announces Increase in Share Repurchase Program WESTBROOK, Maine, May 3, 2017 - IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, today announ
Read more →IDXXIDEXX Laboratories Announces First Quarter Results - Reports revenue growth of 11% on both a reported and organic basis, driven by CAG Diagnostics recurring revenue growth of 13% reported and 14% organic - Achieves 2,340
IDEXX Laboratories Announces First Quarter Results WESTBROOK, Maine, April 28, 2017 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, reports revenues for the first qua
Read more →IDXXIDEXX Laboratories Announces Fourth Quarter and Full Year 2016 Results - Achieves Q4 revenue growth of 11% on a reported basis and 12% on an organic basis, driven by CAG Diagnostics recurring revenue growth of 13% on bot
IDEXX Laboratories Announces Fourth Quarter and Full Year 2016 Results WESTBROOK, Maine, Feb. 2, 2017 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, reports revenues
Read more →IDXXIDEXX Laboratories Elects Lawrence D. Kingsley to Board of Directors
IDEXX Laboratories Elects Lawrence D. Kingsley to Board of Directors WESTBROOK, Maine, Oct. 19, 2016 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX) today announced the unanimous election of Lawrence D. Kingsley as a member of the Company's Board of Directors, effective
Read more →IDXXIDEXX Laboratories Announces Second Quarter Results -- Overall revenues increase 13%, driven by CAG Diagnostics recurring revenue growth of 13% reported and 12% organic -- EPS increases 23% to $0.74, up 33% on a constant
IDEXX Laboratories Announces Second Quarter Results WESTBROOK, Maine, Aug. 2, 2016 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX) today reported revenues for the second quarter of 2016 of $467 million, an increase of 13% compared to the prior year period. Organic revenu
Read more →IDXXIDEXX Laboratories Announces First Quarter Results -- Achieves 11% organic growth for total Company and CAG Diagnostics recurring revenues -- Premium instrument placements increase 18%, supported by 25% growth in Catalys
IDEXX Laboratories Announces First Quarter Results WESTBROOK, Maine, April 29, 2016 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX) today reported revenues for the first quarter of 2016 of $418 million, an increase of 9% compared to the prior year period. Organic revenue
Read more →IDXXIDEXX Laboratories Announces Fourth Quarter and Full Year 2015 Results -- Achieves 11% normalized organic revenue growth for the quarter, supported by 12.5% normalized organic growth in CAG Diagnostics recurring revenues
IDEXX Laboratories Announces Fourth Quarter and Full Year 2015 Results WESTBROOK, Maine, Jan. 29, 2016 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX) today reported revenues for the fourth quarter of 2015 of $400 million, an increase of 14% 1 compared to the prior year
Read more →IDXXIDEXX Laboratories Announces Third Quarter Results -- Achieves 12% normalized organic revenue growth and Adjusted EPS of $0.54, reflecting continued strong gains in instrument consumable and reference lab sales, and impr
IDEXX Laboratories Announces Third Quarter Results WESTBROOK, Maine, Oct. 28, 2015 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX) today reported revenues for the third quarter of 2015 of $406 million, an increase of 6% compared to the prior year period. Impacts from the
Read more →IDXXIDEXX Laboratories Announces Second Quarter Results - Catalyst instrument placements at all-time record level of over 1,100 units and premium hematology placements at Q2 record level of over 900 units - Achieves 13% norm
IDEXX Laboratories Announces Second Quarter Results WESTBROOK, Maine, July 30, 2015 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX) today reported revenues for the second quarter of 2015 of $413 million, an increase of 6% compared to the prior year period. Impacts from t
Read more →IDXXIDEXX Laboratories Elects Bruce L. Claflin to Board of Directors
IDEXX Laboratories Elects Bruce L. Claflin to Board of Directors WESTBROOK, Maine, July 14, 2015 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX) today announced the unanimous election of Bruce L. Claflin as a member of the Company's Board of Directors, effective July 14,
Read more →IDXXEXECUTION COPY IDEXX LABORATORIES, INC. $50,000,000 3.32% Series A Senior Notes due
IDEXX LABORATORIES, INC. $50,000,000 3.32% Series A Senior Notes due July 21, 2021 $75,000,000 3.76% Series B Senior Notes due July 21, 2024 88,857,295.18 1.785% Series C Senior Notes due June 18, 2025 $75,000,000 (or the Foreign Currency Equivalent thereof) Private Shelf Fac
Read more →IDXXIDEXX Laboratories Announces Two-for-One Stock Split and Increase in Share Repurchase Program
IDEXX Laboratories Announces Two-for-One Stock Split and Increase in Share Repurchase Program WESTBROOK, Maine, May 6, 2015 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX) today announced that its Board of Directors approved a two-for-one split of its outstanding common
Read more →IDXXIDEXX Laboratories Announces First Quarter Results -- Premium instrument placements increase 24%, supported by 35% growth in Catalyst placements -- Achieves 14% normalized organic growth in CAG Diagnostics recurring reve
IDEXX Laboratories Announces First Quarter Results WESTBROOK, Maine, April 28, 2015 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX) today reported revenues for the first quarter of 2015 of $382 million, an increase of 6% compared to the prior year period. Impacts from th
Read more →IDXXIDEXX Laboratories Announces Fourth Quarter Results -- Achieves full-year normalized organic revenue growth of 10%, driven by 11% normalized organic growth in CAG Diagnostics recurring revenue -- Adjusted EPS of $3.99 pe
IDEXX Laboratories Announces Fourth Quarter Results WESTBROOK, Maine, Jan. 30, 2015 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX) today reported revenues for the fourth quarter of 2014 of $352 million. Continued strong normalized organic revenue growth 1,2 was offset i
Read more →IDXXExecution Version IDEXX LABORATORIES, INC. $75,000,000 3.25% Series A Senior Notes due
Execution Version IDEXX LABORATORIES, INC. $75,000,000 3.25% Series A Senior Notes due February 12, 2022 $75,000,000 3.72% Series B Senior Notes due February 12, 2027 $50,000,000 (or Foreign Currency Equivalent) Private Shelf Facility MULTICURRENCY NOTE PURCHASE AND PRIVATE
Read more →Competitive Position
How IDXX ranks across every disease it competes inCompetitive Position is a premium feature
See how IDXX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial